Global Health Ventures Inc.
OTC Bulletin Board : GHLV

Global Health Ventures Inc.

December 01, 2010 09:26 ET

Global Health Ventures Reports Positive Data on Relax-B

VANCOUVER, BRITISH COLUMBIA--(Marketwire - Dec. 1, 2010) - Global Health Ventures Inc. (OTCBB:GHLV) (the "Company") is a specialty pharmaceutical company focused on sublingual (under the tongue) drug delivery. The Company is pleased to announce that it has completed the research on the development of its second drug, Relax-B. Relax-B is the Company's second most advanced drug for anxiety attacks. Relax-B is the sublingual formulation of Propranolol currently marketed for hypertension. Oral Propranolol is a very slow acting drug with blood absorption of about 2 hours. Our company decided to develop a rapid absorption formulation using our proprietary sublingual technology. The Company had engaged a third party company to conduct a side by side study of Relax-B with Propranolol to compare dissolution and bioavailability. The fact that the new formulation is able to deliver the drug faster is highly dependent on the drug's dissolution profile and subsequently its bioavailability. The study was conducted under USP protocol and is now completed. The study showed Relax-B to be 5 times (500%) faster/quicker in dissolution and bioavailability than the oral Propranolol. That suggests that we can now use less quantity of the drug and achieve faster and more effective results. A low dosage Relax-B is being developed as an anti-anxiety treatment as well as for hypertension. The drug shall now move to the clinical production and we are planning to initiate human clinical trials in 2011.

"We are very pleased with the results of our second drug Relax-B. We are now confident that our technology shall apply to a vast number of drugs that can bypass the gastrointestinal and liver side effects and result in faster onset of action," said Dr. Hassan Salari, Global Health President & CEO.

About Global Health Ventures

Global Health Ventures is a specialty pharmaceutical company with expertise in drug delivery and formulation. The Company has a proprietary platform technology for drug delivery via the sublingual (under the tongue) route. This unique method delivers drugs to the bloodstream quickly with minimal drug breakdown in the liver or gastrointestinal system, a process that can greatly reduce side effects associated with the drugs. The Company's lead therapeutic product is a male sexual enhancement drug that is delivered via sublingual route and is called X-Excite. In experimental studies, X-Excite has been shown to reach the blood stream rapidly, producing maximal effect and having less of the unwanted side effects associated with oral delivery route. X-Excite is presently in clinical development in Europe. The Company's second drug "Relax-B" is also under development in Canada for anxiety. And, the third drug will be an anti-migraine drug. The Company plans to use the same technology to deliver a vast number of other FDA approved and non-approved drugs that require faster delivery, or reduced hepatic and gastrointestinal side effects. These include stress relief, sleeping disorders, pain killers, anti-allergy medications, energy boosters and addiction replacement therapies.

Notice Regarding Forward Looking Statements - This press release includes forward-looking statements that involve a number of risks and uncertainties, including the success of the products in commercializing and developing. Further, the risks involve the ability of the Company to raise capital to fund its operations and the capital requirements for the development and marketing of its products. Investors are encouraged to review the risk factors listed or described from time to time in the Company's filings (10K) with the Securities and Exchange Commission.

Contact Information